Phase I/II Trial of a Therapeutic DNA Vaccine for Chronic Hepatitis C Virus (HCV) Infection
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 28 Apr 2016
At a glance
- Drugs INO 8000 (Primary) ; INO 9012
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Inovio Pharmaceuticals
- 28 Apr 2016 According to Inovio Pharmaceuticals media release, in April 2016, the company partnered with National Cancer Institute and Mayo Clinic to initiate this trial.
- 16 Apr 2015 Status changed from planning to not yet recruiting, according to ClinicalTrials.gov record.
- 13 Nov 2014 New trial record